ANDOVER, Mass., March 4 /PRNewswire/ -- TransMedics, Inc., a leading medical device company focusing on delivering the next standard of care for solid organ transplantation worldwide, announced today the closing of a $36 million financing round. The financing was lead by Foundation Capital and Kleiner Perkins Caufield & Byers (KPCB) and also included investments by Flagship Ventures and by several existing investors.
"We are excited at the high level of confidence our investors have in our transforming technology and market potential," said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc. "This financing enables us, over the next two years, to expand our commercial presence into the US market with our heart OCS(TM) device and to globally launch the OCS(TM) lung device."
"The field of solid organ transplantation is undergoing revolutionary advances, and TransMedics is positioned to emerge as the world leader in the field. We at Kleiner Perkins are extremely motivated to invest in companies that matter, that improve peoples lives in a significant way -- TransMedics clearly meets that criteria," said Mr. Joe Lacob, Partner, KPCB.
About Foundation Capital: Founded in 1995, Foundation Capital is a venture capital firm committed to supporting entrepreneurs and their companies, targeting innovative opportunities in cleantech, consumer Internet and infrastructure; telecommunications and networking; and enterprise software and on demand services. Foundation Capital funds total more than $2.4 billion. For more information, please visit www.foundationcapital.com.
CONTACT: Media, Neal Beswick of TransMedics, Inc., +1-978-552-0905,
Web site: http://www.TransMedics.com/